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treatment plans on which we delineated the anal-sphincter region 
(ASR) and the rectum following the outer border (Figure). We 
delineated the anal-sphincter region extending from the end of the 
rectal ampulla to the anus. The rectum was delineated from the 
recto-sigmoid junction to the end of the rectal ampulla. Fecal leakage 
was assessed in the questionnaire by the question 'Have you had fecal 
leakage while awake, the previous six months?'. The responses were 
dichotomized at a level of symptom occurrence at least once a month. 
 
 Results: Prostate-cancer survivors who reported faecal leakage at 
least once a month had received an average mean dose to the rectum 
of 47.8 Gy compared to 44.0 Gy for those who reported faecal leakage 
less than once a month (two-sided t test p=0.009). When stratifying 
the mean absorbed dose to the rectum in 5 Gy-bins we found a 
statistically significantly higher occurrence of faecal leakage 
compared to population-based controls from 35 Gy and above. Men 
who had received a mean absorbed dose of ≥40 Gy to the anal-
sphincter region (IJROBP 2012;84:e131) and ≥35 Gy to the rectum had 
the highest prevalence ratio 4.6 (95% CI 2.2–9.5) of faecal leakage 
compared to controls (Table). 
 
  
Conclusions: Our results suggest that the combination of dose to the 
anal-sphincter region and dose to the rectum contributes to the 
excess risk of long-term faecal leakage after radiation therapy for 
prostate cancer. These findings indicate that future prediction models 
for this symptom may need to consider both these organs-at-risk.  
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Purpose/Objective: Since the objective of conservative treatment, in 
addition to local control and survival, is the aesthetic result, the 
acute toxicity and cosmetic outcome evaluation is essential. Here we 
present the results of the first 256 breast cancer pts treated with 
HPRT scheme. 
Materials and Methods: Clinical records of 294 breast cancer pts 
receiving postoperative HPRT after conservative surgery pts had been 
evaluated. Age: Mean 57.26 years (range 30-80). Tumor location: 
54.08% (158) of the pts on the right breast and 45.92% (136) on the 
left. Surgical treatment: Lumpectomy+sentinel node technique (181 
pts, 61.56%), quandrantectomy+axillary dissection (60 pts, 20.40%), 
and lumpectomy+axillary dissection (53 pts, 18.04%). Histology: CDI 
(94.89%). Tumor size: 1.39 cm. (range 0.4-5.8). Histological grade: GI 
29.25%, G2 40.81% and G3 29.94%. Resection margins: 18 pts (6.12%) 
with positive margins. Hormone receptors: (-) in 6.46%. HER-2: (-) in 
11.22%. Sentinel lymph node: (+) in 1.70%. Isolated axillary nodes: 
Mean 12.5 (range 1-24). Positive 1.02 (range 0-2). Stage: I 70.06%, II 
27.55%, and III 2.39%. RTP schedule: Breast: 40.5 Gy in 15 fractions of 
2.7 Gy. Boost: 103 pts (35.03%) received no boost, 176 (59.86%) 
received 10 Gy/5fr and 15 (5.11%) received 14 Gy/7fr. Adjuvant 
chemotherapy: 52.38%. Hormone therapy: 58.87%. Follow-up 
schedule: Weekly based during RTP, 1 month after the end of RTP 
and, later, every three months. 
Results: 77 pts (26.19%) developed radiodermatitis. Of these, 88.31% 
Grade I and 11.69% Grade II. The mean dose at which radiodermatitis 
appeared was 34.92 Gy (range 13.5-46.5). After 12 months of follow-
up, only 17 pts (5.78%) had a slight residual hyperpigmentation in the 
treated area. 
Conclusions: With careful planning, acute toxicity and cosmetic 
outcome of HPRT are perfectly comparable to that obtained with 
conventional fractionation. Thus, in addition, this treatment scheme 
reduces total time of treatment and, therefore, a decrease in the 
waiting list is achieved. 
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Purpose/Objective: In breast cancer pts it’s crucial, because of its 
high survival, to study the possibilities of developing a radiation-
induced cancer. In its development are implicated low range radiation 
doses (up to 20 to 30 Gy, depending on the tumor type) received by 
the healthy tissue, except for second sarcoma, induced at higher 
doses. The dose over the entire breast is 50 Gy, and therefore this 
dose is outside the above range. The purpose of this study is to 
analyze the effects of boost performed, whose value is between 10 
and 16 Gy [included within the dosage range previously mentioned as 
potential inducer of second cancers in areas as homolateral (HL) and 
contralateral lung (CL) and breast (CB)] and find out if there is any 
difference if its delivered by PH or E and, therefore, one technique is 
more cancer inductive than the other. We present the results of the 
first five pts. 
Materials and Methods: 5 consecutive breast cancer pts, treated with 
conservative intend, undergoing radiotherapy, were enrolled. The 
Eclipse (Varian) version 10.0 planning system was used for treatment 
planning and dose-volume histograms (DVH) analysis. Statistical 
analysis of data was performed by MATLAB software. For each pt, two 
different boost planning options were calculated; one by PH and 
another by E. DVH of each were analyzed and determined: a) Volume 
(cm3) of HL and CL receiving a dose between 5 and 20 Gy (V5-20 Gy). 
b) Volume (cm3) of CB receiving a dose between 5 and 10 Gy (V5-10 
Gy). c) Volume (cm3) of esophagus receiving a dose between 10 and 20 
Gy (V10-20 Gy). These cancer induction dose ranges had been 
reported by Schneider et al in 2011. Also, the mean integral dose in 
the treated breast (MIDB) and the mean integral dose received in the 
whole simulation volume (MIDWSV) were determined for each patient. 
A Wilcoxon-Mann Whitney test was performed for each organ. 
Results: The Wilcoxon-Mann Whitney test was performed for HL, MIDB 
and MIDWSV because, in the other organs we observed that the 
volumes receiving doses considered limiting were null. The test 
showed that the null hypothesis was true (median equal for both data 
samples, with a significance level of 5%) for HL, but false for MIDB and 
MIDWSV. Therefore, in the group of patients, no significant 
differences were found in HL between both boost treatment 
modalities (PH or E), but they were found for MIDB (increased for E) 
and for MIDWSV (increased for PH). 
Conclusions: There is a significant difference between E or PH boost 
regarding low doses in distant organs. Not differences were found 
regarding lung doses for both techniques. E boost possibly is more 
related to higher probability of homolateral induced sarcoma. Integral 
dose is also higher in PH boost. Integral dose has been linked to 
general cancer induction. This low dose distribution might be used as 
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optimization criteria for a certain patient regarding election between 
E or PH boost with similar CTV coverage. 
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Purpose/Objective: Head and neck cancer treatment is associated 
with significant morbidities. Both exclusive radiotherapy (RT) and 
chemoradiotherapy (CHRT) treatments can produce, as side effects, 
increased rates of long-term dysphagia. The purpose of the study here 
presented was to evaluate the ability of videofluoroscopy (VDF) in 
detecting and measuring swallowing dysfunction secondary to 
treatments. 
Materials and Methods: Eight head-and-neck cancer patients, who 
underwent radical RT till 70 Gy (5 fractions per week, 2 Gy per 
fraction), and concurrent chemotherapy (CHT) when indicated, were 
included. Treatment schedules administered to each patient (RT total 
dose, radiation fields, delivery techniques, CHT schemes) were 
decided according the NCCN recommendations. Half of patients 
received exclusive RT and the other half concomitant CHRT.  
In order to evaluate a possible swallowing dysfunction, VDF were 
performed before and after the treatment. Patients presenting 
swallowing dysfunction before the treatment were excluded. Post-
treatment evaluation was undertaken twice: early (1-3 months) and 
late post-therapy (4-9 months). The VDF explored swallowing 
dysfunction with the standard different textures. 
Results: Three patients developed some swallowing dysfunction in 
early post-therapy evaluation and, in the late post-therapy 
evaluation, 7 patients showed propulsive defect of the pharynx and 6 
of them had also residue. Only one patient had symptoms related to 
this dysfunction. No case of pneumonia by aspiration was reported. 
Conclusions: Swallowing dysfunction is a prevalent side effect after 
intensive RT and CHRT treatment in head-and-neck cancer patients. In 
our first 8 patients included, most frequent swallowing dysfunction 
was the propulsive defect of the pharynx asymptomatic in most of the 
cases. VDF was very effective in detecting, measuring and controlling 
this side effect. However, in order to confirm these results, inclusion 
of more patients is required. Therefore, patient enrolment continues. 
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Purpose/Objective: In daily clinical practice, acute adverse skin 
reactions due to radiation therapy (RT) are graded by the experienced 
eye of the radiation oncologist. However, such subjective grading 
provides only rough estimates of RT response. In addition, a great 
range of skin reactions is observed even between patients undergoing 
the same treatment. Aim of our study was to implement a 
quantitative method, based on reflectance spectrophotometry (RS), 
for objective in vivo measurements of skin erythema and pigmentation 
due to RT. Correlations between RS measurements and both clinicians' 
skin toxicity perceptions and delivered superficial doses were 
investigated. 
Materials and Methods: Patients treated with tangential fields to the 
breast parenchyma were included. RT prescribed dose: 50-60Gy, 2Gy 
per fraction. Skin RS measurements were obtained by means of a 
commercially available system (SpectroShade, MHT) which allows to 
acquire skin reflectance data between 483 and 950nm inside an useful 
field of view of 18x14mm2. Measurements were performed before RT 
and approximately every 6 (range 4-8) RT fractions up to the end of 
the RT treatment. At the same time, skin acute toxicity grade (ATG) 
reactions were visually assessed and recorded by the physician using 
RTOG scoring system.Both instrumental RS measurement and 
subjective ATG were performed at five different fixed points within 
the area treated with RT. RS relative changes at two selected band 
widths centred at 560nm (haemoglobin absorption peak) and720nm 
(mainly melanin absorption) were analysed and their correlation with 
ATG and delivered superficial dose was investigated. 
Results: Preliminary analysis of measurements at inframammary fold 
on 11 pts is here presented. SkinRS relative changes at 560nm 
(RSRC560nm) were a strong indicator of skin erythema and correlated 
well with clinical ATG evaluation (fig 1a). No evidence of a 
relationship between superficial absorbed doses (at inframammary 
fold) and RSRC560nm was obtained. However, after an initial 30Gy 
irradiation, where patient-to-patient variability to RT resulted to be 
extremely high, RSRC560nm data clearly indicate the existence of 3 
different groups of patients, i.e. over- normal- and under- reacting to 
RT, with RSRC560nm values <0.6 (3pts), in 0.8-0.9 range (6pts) and 
>1.1 (2pts), respectively (fig 1b). Finally, skin RS relative changes at 
720nm (RSRC720nm) resulted to be mostly related to skin 
pigmentation and started to slightly modify at the very end of the RT.  
  
Conclusions: RS is a good and objective tool to evaluate skin 
erythema and pigmentation changes. Although preliminary, these data 
are very interesting and do deserve further investigation. More 
patients will be recruited to investigate the origin of the variation in 
patients' radiosensitivity, at the genetic level. 
This study was funded by a grant of Mrs M. Bonatti and Mr G. Mameli 
and by the National Cancer League 
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Purpose/Objective: This study explores the relationship between the 
severity of late normal tissue damage in the irradiated breast, i.e. 
fibrosis leading to breast shrinkage, and the variation in residual DSBs, 
and in damage response markers (p21 and p53) of dermal fibroblasts 
isolated from skin biopsies of the patient and irradiated in-vivo or in-
vitro. 
Materials and Methods: 35 breast cancer patients with minimal 
(controls) or marked late fibrotic changes in the irradiated breast 
(cases) were selected 5 to 10 years after postoperative radiotherapy 
after breast preserving surgery. Skin biopsies of 4 mm diameter were 
taken 24 h or 12 weeks after irradiation of a field of 4 x 2 cm² in the 
lower back with 4 Gy using 6 MeV electrons. Punch biopsies were 
taken from both the irradiated and the contralateral unirradiated 
skin. Primary fibroblast cultures were established by outgrowth from 
those fresh irradiated and unirradiated skin biopsies which were 
collected 12 weeks after exposure. Residual DSBs were quantified in 
tissue sections from irradiated and unirradiated skin as well as in 
primary fibroblasts cultures which were irradiated in-vitro with 4 Gy 
as well by scoring 53BP1 foci. P53 and p21 levels were measured in 
fibroblast cultures. 
Results: 24 h after in-vitro irradiation the residual number of 53BP1 
foci increased compared to levels in unirradiated fibroblast cultures. 
The increase is larger in fibroblasts isolated from the cases than from 
the control patients. By contrast, the in-vivo irradiated samples which 
were established 12 weeks after irradiation have essentially the same 
number of foci as the unirradiated cells. The expression of p53 is 
